Price
Financials
Consolidated, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 7.62 | 6.56 | 4.42 | 2.44 | 3.00 | 1.50 | 0.48 | 8.94 | 55.36 | 45.25 | 6.36 | 9.29 |
| Expenses | 7.30 | 6.27 | 4.56 | 2.08 | 2.89 | 1.37 | 1.44 | 8.79 | 54.75 | 45.04 | 6.59 | 9.36 |
| Operating Profit | 0.32 | 0.29 | -0.14 | 0.36 | 0.11 | 0.13 | -0.96 | 0.15 | 0.61 | 0.21 | -0.23 | -0.07 |
| OPM % | 4.20% | 4.42% | -3.17% | 14.75% | 3.67% | 8.67% | -200.00% | 1.68% | 1.10% | 0.46% | -3.62% | -0.75% |
| Other Income | 0.05 | 0.02 | -0.03 | 0.00 | 0.00 | 0.01 | 0.05 | 0.02 | 0.01 | 0.08 | 0.01 | 0.37 |
| Interest | 0.11 | 0.10 | 0.09 | 0.09 | 0.09 | 0.09 | 0.08 | 0.08 | 0.05 | 0.09 | 0.07 | 0.11 |
| Depreciation | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Profit before tax | 0.26 | 0.21 | -0.27 | 0.27 | 0.02 | 0.05 | -0.99 | 0.09 | 0.57 | 0.20 | -0.30 | 0.18 |
| Tax % | 0.00% | 0.00% | 55.56% | 0.00% | 0.00% | 0.00% | 1.01% | 0.00% | 0.00% | 0.00% | 50.00% | 22.22% |
| Net Profit | 0.26 | 0.21 | -0.41 | 0.27 | 0.02 | 0.04 | -1.00 | 0.09 | 0.56 | 0.20 | -0.45 | 0.15 |
| EPS in Rs | 0.06 | 0.05 | -0.10 | 0.07 | 0.00 | 0.01 | -0.25 | 0.02 | 0.14 | 0.05 | -0.11 | 0.04 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 3 | 6 | 3 | 10 | 10 | 10 | 18 | 28 | 7 | 116 | 116 |
| Expenses | 0 | 4 | 6 | 3 | 10 | 10 | 10 | 17 | 27 | 8 | 115 | 116 |
| Operating Profit | -0 | -0 | 1 | -0 | -0 | 0 | -0 | 1 | 1 | -0 | 1 | 1 |
| OPM % | -9% | 9% | -0.8% | -3.6% | 0.9% | -0.6% | 3.8% | 3.9% | -4.9% | 0.6% | 0.5% | |
| Other Income | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -0 | -0 | 0 | -0 | -0 | 0 | 0 | 1 | 1 | -1 | 1 | 1 |
| Tax % | 0% | 0% | 13% | 0% | 0% | 42% | 0% | 17% | 21% | 2% | 27% | |
| Net Profit | -0 | -0 | 0 | -0 | -0 | 0 | 0 | 1 | 1 | -1 | 0 | 0 |
| EPS in Rs | -0.32 | -0.08 | 0.05 | -0.11 | -0.05 | 0.02 | 0.08 | 0.15 | 0.14 | -0.17 | 0.10 | 0.12 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | 64% | 87% | 735% | ||
| Compounded Profit Growth | 24% | 37% | -13% | 154% | ||
| Stock Price CAGR | -14% | -35% | -46% | -16% | ||
| Return on Equity | 2% | 6% | 2% | 9% |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.19 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Reserves | -0 | -0 | -0 | -1 | -1 | -1 | -1 | 0 | 1 | -0 | 0 |
| Borrowings | 0 | 1 | 1 | 1 | 0 | 0 | 6 | 8 | 5 | 9 | 10 |
| Other Liabilities | 0 | 3 | 5 | 6 | 9 | 5 | 7 | 10 | 10 | 4 | 8 |
| Total Liabilities | 1 | 7 | 10 | 11 | 12 | 8 | 16 | 22 | 20 | 16 | 22 |
| Fixed Assets | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 1 | 5 | 8 | 9 | 10 | 6 | 13 | 20 | 17 | 14 | 20 |
| Total Assets | 1 | 7 | 10 | 11 | 12 | 8 | 16 | 22 | 20 | 16 | 22 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 0 | -2 | -0 | 1 | 3 | -3 | 2 | -1 | 2 | -2 | -3 |
| Cash from Investing Activity | 0 | 2 | 0 | 0 | 0 | -0 | 0 | 0 | -0 | -0 | -0 |
| Cash from Financing Activity | 0 | 0 | -1 | -1 | -3 | 3 | -2 | 1 | -2 | 2 | 3 |
| Net Cash Flow | 0 | 0 | -1 | -0 | 0 | -0 | -0 | 0 | 0 | -0 | -0 |
| Free Cash Flow | 0 | -2 | -0 | 1 | 3 | -3 | 2 | -1 | 2 | -3 | -3 |
| CFO/OP | 0% | 668% | -15% | -4,300% | -876% | -3,367% | -4,117% | -124% | 203% | 692% | -328% |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 267 | 287 | 782 | 250 | 231 | 275 | 256 | 151 | 398 | 39 | |
| Inventory Days | 215 | 150 | 309 | 38 | 26 | 92 | 55 | 28 | 121 | 11 | |
| Days Payable | 304 | 319 | 878 | 319 | 154 | 207 | 211 | 116 | 140 | 23 | |
| Cash Conversion Cycle | 178 | 118 | 213 | -32 | 103 | 160 | 99 | 64 | 379 | 27 | |
| Working Capital Days | 332 | 237 | 469 | 109 | 104 | 103 | 50 | 44 | 154 | 7 | |
| ROCE % | -10% | 13% | -0% | 6% | 17% | 12% | 11% | 10% | -3% | 6% |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 47.29% | 44.90% | 43.24% | 40.05% | 39.86% | 20.02% | 20.02% | 20.02% | 20.02% | 20.02% | 20.02% | 20.02% |
| Public | 52.70% | 55.10% | 56.75% | 59.95% | 60.13% | 79.98% | 79.98% | 79.98% | 79.98% | 79.98% | 79.98% | 79.98% |
| No. of Shareholders | 5,039 | 5,937 | 6,992 | 16,941 | 16,701 | 20,635 | 20,833 | 20,458 | 20,170 | 19,822 | 19,461 | 19,254 |
Fundamentals
Market Cap₹ 6.92 Cr.
Current Price₹ 1.73
Stock P/E15.0
Book Value₹ 1.09
ROCE6.11 %
ROE9.38 %
Dividend Yield0.00 %
Face Value₹ 1.00
Compounded Sales Growth (TTM)735%
Compounded Profit Growth (TTM)154%
Consolidated figures.
Valuation
Market capRs 7 Cr
Enterprise valueRs 17 Cr
P/E (TTM)14.78x
Price to book1.56x
Price to sales0.06x
EV / EBITDA17.09x
EV / EBIT17.44x
EV / sales0.15x
Earnings yield6.76%
P/E, 3-year average33.72x
P/B, 3-year average3.16x
P/E, 5-year average53.91x
P/B, 5-year average6.01x
Profitability
Operating margin (excl. other income)0.64%
Operating margin (incl. other income)0.73%
EBITDA margin0.85%
Pre-tax margin0.56%
Net profit margin0.40%
Net margin, latest quarter1.61%
ROE9.38%
ROCE6.11%
ROA2.02%
ROE, 3-year average2.13%
ROCE, 3-year average4.53%
ROA, 3-year average0.31%
ROE, 5-year average6.43%
ROCE, 5-year average7.32%
ROA, 5-year average1.36%
ROIC (approx.)4.87%
Tax rate27.27%
Other income / net worth2.52%
Growth
Sales growth (latest year)1468.47%
Sales CAGR, 3 years86.70%
Sales CAGR, 5 years63.60%
Profit CAGR, 3 years-13.38%
Profit CAGR, 5 years37.28%
Sales growth QoQ46.07%
Sales growth YoY (latest quarter)3.92%
Profit growth YoY (latest quarter)66.67%
Per share
EPS (TTM)Rs 0.12
EPS (latest year)Rs 0.10
EPS (latest quarter)Rs 0.04
EPS, 3-year averageRs 0.02
EPS, 5-year averageRs 0.21
Book value per shareRs 1.09
Sales per shareRs 29.07
Cash flow per shareRs -0.65
Free cash flow per shareRs -0.75
Efficiency
Asset turnover5.25x
Fixed asset turnover47.50x
Inventory turnover32.23x
Inventory days11 days
Debtor days39 days
Debtors turnover9.36x
Creditor days23 days
Cash conversion cycle27 days
Working capital days7 days
Leverage
Total debtRs 10 Cr
Cash and bankRs 0 Cr
Net debtRs 10 Cr
Debt to equity2.34x
Net debt / EBITDA10.22x
Interest coverage3.03x
Owners' fund to total sources19.74%
Debt to assets46.13%
Cash flow
Cash from Operating Activity (latest year)Rs -3 Cr
Cash from Investing Activity (latest year)Rs -0 Cr
Cash from Financing Activity (latest year)Rs 3 Cr
Net Cash Flow (latest year)Rs -0 Cr
Free cash flow (latest year)Rs -3 Cr
FCFE (approx.: FCF + change in debt)Rs -1 Cr
Cash from ops / profit, 5 years-2.00x
Statement figures
Net sales (TTM)Rs 116 Cr
Net sales (latest year)Rs 116 Cr
Sales (latest quarter)Rs 9 Cr
Operating profit excl. other income (latest year)Rs 1 Cr
Operating profit (latest quarter)Rs -0 Cr
Other income (TTM)Rs 0 Cr
EBITDA (TTM)Rs 1 Cr
PBDT (TTM)Rs 1 Cr
Profit before tax (TTM)Rs 1 Cr
Tax (latest year)Rs 0 Cr
Net profit (TTM)Rs 0 Cr
Net profit (latest year)Rs 0 Cr
Net profit (latest quarter)Rs 0 Cr
Depreciation (TTM)Rs 0 Cr
Depreciation (latest quarter)Rs 0 Cr
Interest (TTM)Rs 0 Cr
Cost of goods sold (latest year)Rs 114 Cr
Total expenditure (latest year)Rs 115 Cr
Total income (latest year)Rs 116 Cr
Share capitalRs 4 Cr
ReservesRs 0 Cr
Shareholders' fundsRs 4 Cr
Total assetsRs 22 Cr
Net blockRs 2 Cr
ReceivablesRs 12 Cr
InventoryRs 4 Cr
Other liabilitiesRs 8 Cr
Shares outstanding (crore)4.00
Ownership
Promoter holding20.02% (+0.00 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 14.8 is the lowest in its own 3.8-year history
(median 52.6, low 14.8, high 236.4).
P/B 1.56 is the lowest in 8.4 years (median 6.64).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | 530057 | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -3.4% | -2.8% | -0.6 pts |
| 1 month | -4.5% | -6.8% | +2.3 pts |
| 3 months | -6.6% | -7.6% | +1.0 pts |
| 3 years | -84.2% | +14.2% | -98.3 pts |
| 5 years | -88.7% | +27.9% | -116.6 pts |
Red flags
F-score 6 of 8| explain | Weak cash conversion Cash from operations was -1126% of net profit over the last 3 years |
| explain | High accruals Profit exceeded operating cash by 13% of total assets in 2026 |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹9 Cr +3.9% vs Jun 2025.
Net profit ₹0 Cr +66.7%.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Vivanza Biosciences Ltd?
Vivanza Biosciences Ltd (530057) has a market capitalisation of Rs 6.92 Cr. at the 2026-10-01 close.
What is the P/E ratio of Vivanza Biosciences Ltd?
Vivanza Biosciences Ltd trades at a P/E of 15.0 on trailing twelve-month profit, at the 2026-10-01 close.
What were Vivanza Biosciences Ltd's latest quarterly results?
In the Jun 2026 quarter, Vivanza Biosciences Ltd sales was Rs 9 Cr (+3.9% vs Jun 2025) and net profit was Rs 0 Cr.